Published in J Biol Chem on February 09, 2010
Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nat Neurosci (2014) 2.38
Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther (2011) 1.72
Degeneration and repair in central nervous system disease. Nat Med (2010) 1.42
Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells. Mol Brain (2012) 1.36
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med (2010) 1.27
Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J Neurochem (2010) 1.25
Role of astroglia in Down's syndrome revealed by patient-derived human-induced pluripotent stem cells. Nat Commun (2014) 1.18
Neuroinflammation in Huntington's disease. J Neural Transm (Vienna) (2010) 1.16
The role of the immune system in Huntington's disease. Clin Dev Immunol (2013) 1.03
Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics (2012) 0.98
In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. Hum Mol Genet (2010) 0.96
High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease model. PLoS One (2011) 0.95
Modeling Huntington's disease with induced pluripotent stem cells. Mol Cell Neurosci (2013) 0.94
Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. FEBS J (2013) 0.90
Probing the Complexities of Astrocyte Calcium Signaling. Trends Cell Biol (2016) 0.89
An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity. Cell Death Dis (2012) 0.88
Precursor cell biology and the development of astrocyte transplantation therapies: lessons from spinal cord injury. Neurotherapeutics (2011) 0.86
Early activation of microglia and astrocytes in mouse models of spinocerebellar ataxia type 1. Neuroscience (2015) 0.86
Enhanced Ca(2+)-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse model. Neurobiol Dis (2013) 0.86
Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors. Front Cell Neurosci (2013) 0.86
Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity. J Huntingtons Dis (2016) 0.85
Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions. J Cereb Blood Flow Metab (2014) 0.85
Mouse models of polyglutamine diseases: review and data table. Part I. Mol Neurobiol (2012) 0.84
Mitochondrial bioenergetics and dynamics in Huntington's disease: tripartite synapses and selective striatal degeneration. J Bioenerg Biomembr (2010) 0.83
Protection by glia-conditioned medium in a cell model of Huntington disease. PLoS Curr (2012) 0.83
Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function. ASN Neuro (2011) 0.82
Dysfunctional Calcium and Glutamate Signaling in Striatal Astrocytes from Huntington's Disease Model Mice. J Neurosci (2016) 0.82
In vivo astrocytic Ca(2+) signaling in health and brain disorders. Future Neurol (2013) 0.81
Induced pluripotent stem cells for modeling neurological disorders. World J Transplant (2015) 0.79
Distinct roles for Toll and autophagy pathways in double-stranded RNA toxicity in a Drosophila model of expanded repeat neurodegenerative diseases. Hum Mol Genet (2013) 0.78
Disruption of astrocyte-neuron cholesterol cross talk affects neuronal function in Huntington's disease. Cell Death Differ (2014) 0.78
The long and the short of aberrant ciliogenesis in Huntington disease. J Clin Invest (2011) 0.77
Huntington's Disease: An Immune Perspective. Neurol Res Int (2011) 0.76
Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes. Acta Pharmacol Sin (2012) 0.75
Mutant Huntingtin Impairs BDNF Release from Astrocytes by Disrupting Conversion of Rab3a-GTP into Rab3a-GDP. J Neurosci (2016) 0.75
Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models. Front Neurosci (2016) 0.75
Aberrant iPSC-derived human astrocytes in Alzheimer's disease. Cell Death Dis (2017) 0.75
Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific. Glia (2016) 0.75
Striatal infusion of glial conditioned medium diminishes huntingtin pathology in r6/1 mice. PLoS One (2013) 0.75
GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions. Cell Death Dis (2016) 0.75
Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease. Hum Mol Genet (2016) 0.75
The heat shock response in neurons and astroglia and its role in neurodegenerative diseases. Mol Neurodegener (2017) 0.75
Microglial Activation in the Pathogenesis of Huntington's Disease. Front Aging Neurosci (2017) 0.75
A Refined Bead-Free Method to Identify Astrocytic Exosomes in Primary Glial Cultures and Blood Plasma. Front Neurosci (2017) 0.75
Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell (1997) 9.57
Trinucleotide repeat disorders. Annu Rev Neurosci (2007) 9.45
Huntington disease. J Neuropathol Exp Neurol (1998) 6.54
Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (2003) 6.35
Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet (1999) 4.06
Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet (2001) 3.84
Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol (2006) 3.42
Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat Neurosci (2006) 3.05
Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol (2005) 2.57
Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci (2003) 2.20
Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol (2002) 2.19
Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol (2001) 2.17
Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron (2005) 2.11
Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A (2009) 1.87
Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet (1998) 1.83
Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis (2001) 1.71
Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain (2002) 1.71
Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Hum Mol Genet (2008) 1.70
Rodent genetic models of Huntington disease. Neurobiol Dis (2008) 1.58
Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat Neurosci (2007) 1.46
Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J Neurosci (2008) 1.41
Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegener (2007) 1.39
Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener (2006) 1.35
Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease--an in situ hybridization study. J Neuropathol Exp Neurol (1997) 1.28
Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol (1991) 1.27
Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J Neurosci (2008) 1.16
GFAP Transgenic Mice Methods (1996) 1.13
Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res (2007) 1.10
Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum Mol Genet (2005) 1.08
Huntingtin protein colocalizes with lesions of neurodegenerative diseases: An investigation in Huntington's, Alzheimer's, and Pick's diseases. Exp Neurol (1998) 0.99
Expression of the Huntington's disease gene is regulated in astrocytes in the arcuate nucleus of the hypothalamus of postpartum rats. FASEB J (1999) 0.87
Protective effects of cannabinoid receptor agonists against cocaine and other convulsant-induced toxic behavioural symptoms. J Pharm Pharmacol (2001) 0.82
Chronobiological variations in the convulsive effect of monosodium L-glutamate when administered to adult rats. Arch Med Res (1995) 0.78
Monosodium-L-glutamate-induced convulsions--I. Differences in seizure pattern and duration of effect as a function of age in rats. Gen Pharmacol (1984) 0.78
Towards a transgenic model of Huntington's disease in a non-human primate. Nature (2008) 4.47
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet (2003) 4.07
Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci (2008) 3.54
Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet (2004) 2.88
Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol (2005) 2.57
Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A (2003) 2.35
Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci (2003) 2.20
Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol (2002) 2.19
N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci (2008) 2.18
Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron (2005) 2.11
Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J (2008) 2.03
Interaction of Huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons. J Biol Chem (2005) 1.98
Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A (2009) 1.87
Hypothalamic huntingtin-associated protein 1 as a mediator of feeding behavior. Nat Med (2006) 1.86
Proteasomal dysfunction in aging and Huntington disease. Neurobiol Dis (2010) 1.85
Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J Cell Biol (2003) 1.77
Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Hum Mol Genet (2008) 1.70
Transgenic rat model of Huntington's disease. Hum Mol Genet (2003) 1.66
Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet (2005) 1.62
Dicer ablation in oligodendrocytes provokes neuronal impairment in mice. Ann Neurol (2009) 1.62
Adenosine A(2A) receptor mediates microglial process retraction. Nat Neurosci (2009) 1.56
Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J Cell Biol (2008) 1.51
Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci (2002) 1.48
Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat Neurosci (2007) 1.46
Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J Neurosci (2008) 1.41
Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Hum Mol Genet (2005) 1.39
Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegener (2007) 1.39
Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener (2006) 1.35
Lack of huntingtin-associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease. J Neurosci (2003) 1.35
Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Hum Mol Genet (2010) 1.33
Characterization of a brain-enriched chaperone, MRJ, that inhibits Huntingtin aggregation and toxicity independently. J Biol Chem (2002) 1.29
Regulation of intracellular trafficking of huntingtin-associated protein-1 is critical for TrkA protein levels and neurite outgrowth. J Neurosci (2006) 1.23
Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease. Hum Mol Genet (2008) 1.23
Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol (2008) 1.22
Expression of the chemokine receptor Cxcr4 mRNA during mouse brain development. Brain Res Dev Brain Res (2004) 1.20
Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH. Proc Natl Acad Sci U S A (2006) 1.20
Huntingtin-associated protein 1 interacts with Ahi1 to regulate cerebellar and brainstem development in mice. J Clin Invest (2008) 1.19
Huntingtin and its role in neuronal degeneration. Neuroscientist (2004) 1.16
Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum Mol Genet (2002) 1.14
Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum Mol Genet (2003) 1.11
Trends in the incidence of hospitalized acute myocardial infarction and stroke in Korea, 2006-2010. J Korean Med Sci (2013) 1.10
TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J Cereb Blood Flow Metab (2006) 1.10
Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments. Hum Mol Genet (2010) 1.08
Mouse meningiocytes express Sox2 and yield high efficiency of chimeras after nuclear reprogramming with exogenous factors. J Biol Chem (2008) 1.05
Regulation of intracellular HAP1 trafficking. J Neurosci Res (2007) 0.99
Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity. J Biol Chem (2008) 0.98
SCFSlimb ubiquitin ligase suppresses condensin II-mediated nuclear reorganization by degrading Cap-H2. J Cell Biol (2013) 0.96
Huntingtin-associated protein-1 interacts with pro-brain-derived neurotrophic factor and mediates its transport and release. J Biol Chem (2009) 0.96
Incidence of hypertension in Korea: 5-year follow-up study. J Korean Med Sci (2011) 0.96
Intracellular degradation of misfolded proteins in polyglutamine neurodegenerative diseases. Brain Res Rev (2008) 0.96
Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. Hum Mol Genet (2011) 0.96
Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol Ther (2007) 0.94
AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells. J Exp Med (2008) 0.94
Sex-dependent effect of BAG1 in ameliorating motor deficits of Huntington disease transgenic mice. J Biol Chem (2008) 0.92
Neuronal Abelson helper integration site-1 (Ahi1) deficiency in mice alters TrkB signaling with a depressive phenotype. Proc Natl Acad Sci U S A (2010) 0.92
Differential ubiquitination and degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A. Proc Natl Acad Sci U S A (2014) 0.91
Impaired mitochondrial trafficking in Huntington's disease. Biochim Biophys Acta (2009) 0.91
Prevalence and predictors of anxiety and depression among family caregivers of cancer patients: a nationwide survey of patient-family caregiver dyads in Korea. Support Care Cancer (2013) 0.91
Factors associated with compliance with recommendations for liver cancer screening in Korea: a nationwide survey in Korea. PLoS One (2013) 0.91
Activation of gene transcription by heat shock protein 27 may contribute to its neuronal protection. J Biol Chem (2009) 0.90
Huntingtin-associated protein-1 deficiency in orexin-producing neurons impairs neuronal process extension and leads to abnormal behavior in mice. J Biol Chem (2010) 0.88
Immunohistochemical localization of huntingtin-associated protein 1 in endocrine system of the rat. J Histochem Cytochem (2005) 0.87
Suicidal ideation and suicide attempts in anxious or depressed family caregivers of patients with cancer: a nationwide survey in Korea. PLoS One (2013) 0.87
Polyglutamine toxicity in non-neuronal cells. Cell Res (2010) 0.86
Context-dependent dysregulation of transcription by mutant huntingtin. J Biol Chem (2006) 0.86